Detalles de la búsqueda
1.
Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study.
Calcif Tissue Int
; 111(4): 409-418, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35927518
2.
A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.
Pediatr Nephrol
; 37(11): 2547-2557, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35237863
3.
Burosumab Therapy in Children with X-Linked Hypophosphatemia.
N Engl J Med
; 378(21): 1987-1998, 2018 05 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-29791829
4.
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia.
Calcif Tissue Int
; 108(5): 622-633, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33484279
5.
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
Lancet
; 393(10189): 2416-2427, 2019 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31104833
6.
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.
Calcif Tissue Int
; 105(3): 271-284, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31165191
7.
An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis.
Pediatr Nephrol
; 34(1): 145-154, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30141180
8.
Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis.
Pediatr Nephrol
; 34(4): 739-740, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30536181
9.
Vitamin D insufficiency, hemoglobin, and anemia in children with chronic kidney disease.
Pediatr Nephrol
; 33(11): 2131-2136, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30008129
10.
Waist-to-height ratio, body mass index, and cardiovascular risk profile in children with chronic kidney disease.
Pediatr Nephrol
; 33(9): 1577-1583, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29872963
11.
Association of Body Mass Index with Patient-Centered Outcomes in Children with ESRD.
J Am Soc Nephrol
; 27(2): 551-8, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26054540
12.
Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study.
J Am Soc Nephrol
; 27(2): 543-50, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26139439
13.
Prevalence and correlates of 25-hydroxyvitamin D deficiency in the Chronic Kidney Disease in Children (CKiD) cohort.
Pediatr Nephrol
; 31(1): 121-9, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26307635
14.
State level variations in nephrology workforce and timing and incidence of dialysis in the United States among children and adults: a retrospective cohort study.
BMC Nephrol
; 16: 2, 2015 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25589150
15.
Use of pedometers to increase physical activity among children and adolescents with chronic kidney disease.
Pediatr Nephrol
; 29(8): 1395-402, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24648129
16.
The clinical impact of humoral immunity in pediatric renal transplantation.
J Am Soc Nephrol
; 24(4): 655-64, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23449533
17.
Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period.
JBMR Plus
; 8(1): ziad001, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38690124
18.
Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.
J Clin Endocrinol Metab
; 108(11): 2990-2998, 2023 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37084401
19.
Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia.
J Clin Endocrinol Metab
; 108(1): 155-165, 2022 12 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36072994
20.
Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
J Clin Endocrinol Metab
; 107(3): 813-824, 2022 02 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34636899